Multicentric castleman's disease: A challenging diagnosis

G. Müzes, F. Sípos, Judit Csomor, Lídia Sréter

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Multicentric Castleman's disease (MCD) is a sytemic disorder with flares of non-specific symptoms suggestive of a chronic inflammatory syndrome. It is typically accompanied by generalized lymphadenopathy and multiorgan involvement. Histologically, two main variants of Castleman's disease exist, the hyalin vascular type and the plasma cell variant. Upon localization unicentric (localized), and multicentric (diffuse, systemic) subtypes can be distinguished with more different disease outcomes. Patients often exhibit acute phase reactions and several autoimmune phenomena, and are at high risk for developing malignancies. Both the idiopathic and the HHV-8-driven infectious forms of MCD represent distinct disease entities with a less favorable prognosis. The induction of human IL-6 excess via yet unknown upstream mechanisms, and overexpression of viral IL-6 by HHV-8 can pivotally influence MCD biology. Based on the role of IL-6 in pathogenesis, MCD is also designated as IL-6 lymphadenopathy. To date there are no direct therapeutic evidences, but having been translated to daily practice the main regulatory factors may serve as promising therapeutic targets.

Original languageEnglish
Pages (from-to)345-351
Number of pages7
JournalPathology and Oncology Research
Volume19
Issue number3
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Interleukin-6
Human Herpesvirus 8
Giant Lymph Node Hyperplasia
Acute-Phase Reaction
Hyalin
Plasma Cells
Blood Vessels
Multi-centric Castleman's Disease
Therapeutics
Neoplasms
Lymphadenopathy

Keywords

  • Differential diagnosis
  • HHV-8
  • IL-6
  • Monoclonal antibodies
  • Multicentric Castleman's disease
  • Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Multicentric castleman's disease : A challenging diagnosis. / Müzes, G.; Sípos, F.; Csomor, Judit; Sréter, Lídia.

In: Pathology and Oncology Research, Vol. 19, No. 3, 07.2013, p. 345-351.

Research output: Contribution to journalArticle

Müzes, G. ; Sípos, F. ; Csomor, Judit ; Sréter, Lídia. / Multicentric castleman's disease : A challenging diagnosis. In: Pathology and Oncology Research. 2013 ; Vol. 19, No. 3. pp. 345-351.
@article{ab37f7df954e4fcc987fc5f9c88e2ea2,
title = "Multicentric castleman's disease: A challenging diagnosis",
abstract = "Multicentric Castleman's disease (MCD) is a sytemic disorder with flares of non-specific symptoms suggestive of a chronic inflammatory syndrome. It is typically accompanied by generalized lymphadenopathy and multiorgan involvement. Histologically, two main variants of Castleman's disease exist, the hyalin vascular type and the plasma cell variant. Upon localization unicentric (localized), and multicentric (diffuse, systemic) subtypes can be distinguished with more different disease outcomes. Patients often exhibit acute phase reactions and several autoimmune phenomena, and are at high risk for developing malignancies. Both the idiopathic and the HHV-8-driven infectious forms of MCD represent distinct disease entities with a less favorable prognosis. The induction of human IL-6 excess via yet unknown upstream mechanisms, and overexpression of viral IL-6 by HHV-8 can pivotally influence MCD biology. Based on the role of IL-6 in pathogenesis, MCD is also designated as IL-6 lymphadenopathy. To date there are no direct therapeutic evidences, but having been translated to daily practice the main regulatory factors may serve as promising therapeutic targets.",
keywords = "Differential diagnosis, HHV-8, IL-6, Monoclonal antibodies, Multicentric Castleman's disease, Therapy",
author = "G. M{\"u}zes and F. S{\'i}pos and Judit Csomor and L{\'i}dia Sr{\'e}ter",
year = "2013",
month = "7",
doi = "10.1007/s12253-013-9619-z",
language = "English",
volume = "19",
pages = "345--351",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Multicentric castleman's disease

T2 - A challenging diagnosis

AU - Müzes, G.

AU - Sípos, F.

AU - Csomor, Judit

AU - Sréter, Lídia

PY - 2013/7

Y1 - 2013/7

N2 - Multicentric Castleman's disease (MCD) is a sytemic disorder with flares of non-specific symptoms suggestive of a chronic inflammatory syndrome. It is typically accompanied by generalized lymphadenopathy and multiorgan involvement. Histologically, two main variants of Castleman's disease exist, the hyalin vascular type and the plasma cell variant. Upon localization unicentric (localized), and multicentric (diffuse, systemic) subtypes can be distinguished with more different disease outcomes. Patients often exhibit acute phase reactions and several autoimmune phenomena, and are at high risk for developing malignancies. Both the idiopathic and the HHV-8-driven infectious forms of MCD represent distinct disease entities with a less favorable prognosis. The induction of human IL-6 excess via yet unknown upstream mechanisms, and overexpression of viral IL-6 by HHV-8 can pivotally influence MCD biology. Based on the role of IL-6 in pathogenesis, MCD is also designated as IL-6 lymphadenopathy. To date there are no direct therapeutic evidences, but having been translated to daily practice the main regulatory factors may serve as promising therapeutic targets.

AB - Multicentric Castleman's disease (MCD) is a sytemic disorder with flares of non-specific symptoms suggestive of a chronic inflammatory syndrome. It is typically accompanied by generalized lymphadenopathy and multiorgan involvement. Histologically, two main variants of Castleman's disease exist, the hyalin vascular type and the plasma cell variant. Upon localization unicentric (localized), and multicentric (diffuse, systemic) subtypes can be distinguished with more different disease outcomes. Patients often exhibit acute phase reactions and several autoimmune phenomena, and are at high risk for developing malignancies. Both the idiopathic and the HHV-8-driven infectious forms of MCD represent distinct disease entities with a less favorable prognosis. The induction of human IL-6 excess via yet unknown upstream mechanisms, and overexpression of viral IL-6 by HHV-8 can pivotally influence MCD biology. Based on the role of IL-6 in pathogenesis, MCD is also designated as IL-6 lymphadenopathy. To date there are no direct therapeutic evidences, but having been translated to daily practice the main regulatory factors may serve as promising therapeutic targets.

KW - Differential diagnosis

KW - HHV-8

KW - IL-6

KW - Monoclonal antibodies

KW - Multicentric Castleman's disease

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84880329992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880329992&partnerID=8YFLogxK

U2 - 10.1007/s12253-013-9619-z

DO - 10.1007/s12253-013-9619-z

M3 - Article

C2 - 23516126

AN - SCOPUS:84880329992

VL - 19

SP - 345

EP - 351

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -